Edition:
United States

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.74USD
3:27pm EDT
Change (% chg)

$-0.07 (-3.87%)
Prev Close
$1.81
Open
$1.82
Day's High
$1.83
Day's Low
$1.74
Volume
28,285
Avg. Vol
120,281
52-wk High
$3.78
52-wk Low
$1.09

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $55.98
Shares Outstanding(Mil.): 22.48
Dividend: --
Yield (%): --

Financials

  CATB.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.74 -- --
ROI: -107.14 1.58 14.38
ROE: -117.90 2.41 16.07

BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent

* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Apr 17 2018

BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22

* CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC AS OF MARCH 22 - SEC FILING

Apr 04 2018

BRIEF-Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24

* CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

Mar 15 2018

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals‍​

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2CDqdMi) Further company coverage:

Feb 23 2018

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

Feb 13 2018

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

Nov 09 2017

Earnings vs. Estimates